No Effect of Cimetidine on Calcitonin Secretion from Medullary Thyroid Carcinoma
- 12 January 1980
- journal article
- research article
- Published by Wiley in Acta Medica Scandinavica
- Vol. 207 (1-6) , 367-369
- https://doi.org/10.1111/j.0954-6820.1980.tb09739.x
Abstract
The effect of cimetidine on basal and pentagastrin-stimulated serum immunoreactive calcitonin (S-iCT) concentrations was studied in 6 patients with medullary carcinoma of the thyroid (MCT). Basal S-iCT was elevated in all patients and showed a marked increase after i.v. injection of pentagastrin, 0.5 .mu.g/kg body wt. Cimetidine, 200 mg i.v., 30 min before administration of pentagastrin, had no effect on basal or pentagastrin-stimulated S-iCT. The mechanisms of basal and pentagastrin-stimulated calcitonin secretion from MCT do not seem to involve agonism with histamine H2-receptors.Keywords
This publication has 8 references indexed in Scilit:
- The Effects of L-Dopa on inVitroandin VivoCalcitonin Release from Medullary Thyroid Carcinoma*Journal of Clinical Endocrinology & Metabolism, 1979
- Serum Calcitonin after Renal TransplantationActa Medica Scandinavica, 1979
- Serum Calcitonin in Patients with Chronic Renal DiseaseActa Medica Scandinavica, 1979
- Bioavailability of cimetidine in manGastroenterology, 1978
- Screening for medullary carcinoma of the thyroid in families with Sipple's syndrome: evaluation of new stimulation testsEuropean Journal of Clinical Investigation, 1977
- SYNTHETIC HUMAN CALCITONIN: ANALYSIS OF ANTIBODIES OBTAINED FROM VARIOUS ANIMAL SPECIES AND DETERMINATION OF IMMUNOREACTIVE HORMONE IN HUMAN SERAActa Endocrinologica, 1975
- Elevated Histaminase Activity in Medullary Carcinoma of the Thyroid GlandNew England Journal of Medicine, 1970